NCT01277991

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2-period, Crossover, Bioequivalence Study Comparing Phase 2b 1 Mg And 5 Mg Tablet Formulations Of Cp-690,550 Under Fasted Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Accepted

Summary

In this study, a 5 mg dose of CP-690,550 will be given to study subjects on two separate occasions using one of two different strength tablets each time. The amount of CP-690,550 available in the blood following administration of each tablet will be measured and compared. The overall aim of the study is to establish that a similar amount of CP-690,550 is absorbed into the blood following administration of the same dose of each different strength tablet .

Detailed description

This is a bioequivalence study for CP-690,550.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Treatment A	Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
DRUG	Treatment B	Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
DRUG	Treatment B	Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
DRUG	Treatment A	Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2011-01-17
• Last updated: 2011-04-07

Locations

1 site across 1 country: Singapore